Document Detail


Transdermal delivery of sumatriptan for the treatment of acute migraine.
MedLine Citation:
PMID:  20430314     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Migraine is a common, multisymptom disorder that can severely impact the daily activities of migraineurs. Triptans (primarily sumatriptan) are the most commonly prescribed treatment for migraine and are considered a relatively safe and effective initial therapy. Unfortunately, current sumatriptan formulations (i.e., oral, nasal, subcutaneous) may be associated with limitations that can result in patients' delaying or avoiding treatment. For oral formulations, these limitations include difficulty in taking an oral medication due to the nausea and vomiting that often accompany migraine, and inconsistent absorption, whereas nasal and subcutaneous formulations may be associated with low bioavailability and an undesirable rate of adverse events, respectively. An alternative to current formulations is transdermal drug delivery, particularly iontophoresis. Transdermal delivery has several advantages over current formulations, including avoidance of the gastrointestinal tract, controlled and sustained delivery, and convenient administration. This article reviews the in vitro, in vivo, and preclinical data supporting the use of iontophoresis for the delivery of sumatriptan, as well as the recent clinical data for Zelrix (NuPathe Inc., Conshohocken, PA), an iontophoretic sumatriptan patch currently in phase III development for the treatment of migraine.
Authors:
Mark W Pierce
Related Documents :
20685224 - Superparamagnetic iron oxide nanoparticles (spions): development, surface modification ...
16298454 - Micro- and nanoparticulates.
20338204 - Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates.
7632754 - Gamma scintigraphy in the delivery, biodistribution and targeting of therapeutic agents.
24646434 - Liposomes for (trans)dermal drug delivery: the skin-pvpa as a novel in vitro stratum co...
22139684 - Evaluation of metabolism-mediated herb-drug interactions.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics     Volume:  7     ISSN:  1878-7479     ISO Abbreviation:  Neurotherapeutics     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-30     Completed Date:  2010-07-22     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  101290381     Medline TA:  Neurotherapeutics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  159-63     Citation Subset:  IM    
Copyright Information:
Copyright 2010 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier Inc. All rights reserved.
Affiliation:
NuPathe Inc., Conshohocken, Pennsylvania 19428, USA. mpierce@nupathe.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Administration, Cutaneous
Animals
Clinical Trials, Phase III as Topic
Drug Evaluation, Preclinical / methods
Humans
Iontophoresis / methods
Migraine Disorders / drug therapy*
Serotonin Receptor Agonists / administration & dosage*,  pharmacokinetics
Sumatriptan / administration & dosage*,  pharmacokinetics
Treatment Outcome
Chemical
Reg. No./Substance:
0/Serotonin Receptor Agonists; 103628-46-2/Sumatriptan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Meeting acute migraine treatment needs through novel treatment formulations.
Next Document:  CGRP receptor antagonism and migraine.